Cargando…

The Efficacy of Licensed-Indication Use of Donepezil and Memantine Monotherapies for Treating Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease: Systematic Review and Meta-Analysis

BACKGROUND/AIMS: Behavioural and psychological symptoms of dementia (BPSD) in Alzheimer's disease (AD) greatly increase caregiver burden. The abilities of donepezil and memantine to manage BPSD within their licensed indications in AD were compared. METHODS: A systematic review, random effects m...

Descripción completa

Detalles Bibliográficos
Autores principales: Lockhart, I.A., Orme, M.E., Mitchell, S.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199891/
https://www.ncbi.nlm.nih.gov/pubmed/22163246
http://dx.doi.org/10.1159/000330032
_version_ 1782214619995045888
author Lockhart, I.A.
Orme, M.E.
Mitchell, S.A.
author_facet Lockhart, I.A.
Orme, M.E.
Mitchell, S.A.
author_sort Lockhart, I.A.
collection PubMed
description BACKGROUND/AIMS: Behavioural and psychological symptoms of dementia (BPSD) in Alzheimer's disease (AD) greatly increase caregiver burden. The abilities of donepezil and memantine to manage BPSD within their licensed indications in AD were compared. METHODS: A systematic review, random effects meta-analysis and Bucher indirect comparison were conducted. RESULTS: Six randomised controlled studies (4 donepezil and 2 memantine) reported use within the licensed indication and had Neuropsychiatric Inventory (NPI) data suitable for meta-analysis. BPSD showed significant improvement with donepezil compared with placebo [weighted mean difference (WMD) in NPI −3.51, 95% confidence interval (CI) −5.75, −1.27], whereas this was not the case for memantine (WMD −1.65, 95% CI −4.78, 1.49). WMD in NPI for donepezil versus memantine favoured donepezil but was not statistically significant (−1.86, 95% CI −5.71, 1.99; p = 0.34). CONCLUSION: Within its licensed indication, donepezil is efficacious for the management of BPSD in AD compared with placebo.
format Online
Article
Text
id pubmed-3199891
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-31998912011-12-12 The Efficacy of Licensed-Indication Use of Donepezil and Memantine Monotherapies for Treating Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease: Systematic Review and Meta-Analysis Lockhart, I.A. Orme, M.E. Mitchell, S.A. Dement Geriatr Cogn Dis Extra Original Research Article BACKGROUND/AIMS: Behavioural and psychological symptoms of dementia (BPSD) in Alzheimer's disease (AD) greatly increase caregiver burden. The abilities of donepezil and memantine to manage BPSD within their licensed indications in AD were compared. METHODS: A systematic review, random effects meta-analysis and Bucher indirect comparison were conducted. RESULTS: Six randomised controlled studies (4 donepezil and 2 memantine) reported use within the licensed indication and had Neuropsychiatric Inventory (NPI) data suitable for meta-analysis. BPSD showed significant improvement with donepezil compared with placebo [weighted mean difference (WMD) in NPI −3.51, 95% confidence interval (CI) −5.75, −1.27], whereas this was not the case for memantine (WMD −1.65, 95% CI −4.78, 1.49). WMD in NPI for donepezil versus memantine favoured donepezil but was not statistically significant (−1.86, 95% CI −5.71, 1.99; p = 0.34). CONCLUSION: Within its licensed indication, donepezil is efficacious for the management of BPSD in AD compared with placebo. S. Karger AG 2011-07-20 /pmc/articles/PMC3199891/ /pubmed/22163246 http://dx.doi.org/10.1159/000330032 Text en Copyright © 2011 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Original Research Article
Lockhart, I.A.
Orme, M.E.
Mitchell, S.A.
The Efficacy of Licensed-Indication Use of Donepezil and Memantine Monotherapies for Treating Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease: Systematic Review and Meta-Analysis
title The Efficacy of Licensed-Indication Use of Donepezil and Memantine Monotherapies for Treating Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease: Systematic Review and Meta-Analysis
title_full The Efficacy of Licensed-Indication Use of Donepezil and Memantine Monotherapies for Treating Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease: Systematic Review and Meta-Analysis
title_fullStr The Efficacy of Licensed-Indication Use of Donepezil and Memantine Monotherapies for Treating Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease: Systematic Review and Meta-Analysis
title_full_unstemmed The Efficacy of Licensed-Indication Use of Donepezil and Memantine Monotherapies for Treating Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease: Systematic Review and Meta-Analysis
title_short The Efficacy of Licensed-Indication Use of Donepezil and Memantine Monotherapies for Treating Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease: Systematic Review and Meta-Analysis
title_sort efficacy of licensed-indication use of donepezil and memantine monotherapies for treating behavioural and psychological symptoms of dementia in patients with alzheimer's disease: systematic review and meta-analysis
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199891/
https://www.ncbi.nlm.nih.gov/pubmed/22163246
http://dx.doi.org/10.1159/000330032
work_keys_str_mv AT lockhartia theefficacyoflicensedindicationuseofdonepezilandmemantinemonotherapiesfortreatingbehaviouralandpsychologicalsymptomsofdementiainpatientswithalzheimersdiseasesystematicreviewandmetaanalysis
AT ormeme theefficacyoflicensedindicationuseofdonepezilandmemantinemonotherapiesfortreatingbehaviouralandpsychologicalsymptomsofdementiainpatientswithalzheimersdiseasesystematicreviewandmetaanalysis
AT mitchellsa theefficacyoflicensedindicationuseofdonepezilandmemantinemonotherapiesfortreatingbehaviouralandpsychologicalsymptomsofdementiainpatientswithalzheimersdiseasesystematicreviewandmetaanalysis
AT lockhartia efficacyoflicensedindicationuseofdonepezilandmemantinemonotherapiesfortreatingbehaviouralandpsychologicalsymptomsofdementiainpatientswithalzheimersdiseasesystematicreviewandmetaanalysis
AT ormeme efficacyoflicensedindicationuseofdonepezilandmemantinemonotherapiesfortreatingbehaviouralandpsychologicalsymptomsofdementiainpatientswithalzheimersdiseasesystematicreviewandmetaanalysis
AT mitchellsa efficacyoflicensedindicationuseofdonepezilandmemantinemonotherapiesfortreatingbehaviouralandpsychologicalsymptomsofdementiainpatientswithalzheimersdiseasesystematicreviewandmetaanalysis